

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**Stefanie Flohr et al.**

Examiner: **Paul V Ward**

Art Unit: **1624**

Application No.: **10/779,439**

Confirmation **8764**  
No.

Filed: **February 13, 2004**

Title: **NITROGEN-SUBSTITUTED  
HEXAHYDROPYRAZINO[1,2-  
A]PYRIMIDINE-4,7-DIONE  
DERIVATIVES, PROCESSES FOR  
THEIR PREPARATION AND THEIR  
USE AS MEDICAMENTS**

**CERTIFICATE OF EFS-WEB TRANSMISSION**

I hereby certify that the correspondence below is being transmitted via the USPTO's electronic filing system in accordance with 1.6(a)(4), on the date indicated below.

Date of Deposit \_\_\_\_\_

Printed Name of Person \_\_\_\_\_

Signing Certificate \_\_\_\_\_

Signature \_\_\_\_\_/Electronic Signature/

**REQUEST FOR CERTIFICATE OF CORRECTION**  
**UNDER 35 U.S.C. 254/255 and 37 C.F.R. 1.322/323**

Mail Stop  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

The following is a request for a certificate of correction in Serial Number 10/779,439, now patent Number 7,652,007.

A certificate of correction under 35 U.S.C. 254 is respectfully requested in the above-identified patent.

- ☐ All errors were the fault of the USPTO, no fee required. In the event that a further fee is required, please charge the amount to Deposit Account No. **18-1982**.
- ☐ All errors were the fault of the applicant and, accordingly, please charge **\$100.00** to our Deposit Account No. **18-1982**. In the event that a further fee is required, please charge the amount to the same Deposit Account.
- ☒ The errors were the fault of both the applicant and the USPTO and, accordingly, please charge **\$100.00** to our Deposit Account No. **18-1982**. In the event that a further fee is required, please charge the amount to the same Deposit Account.

The exact location where the error appears in the patent and patent application is noted below.

The requested correction is attached on Form PTO 1050.

### **EXACT LOCATION WHERE ERRORS APPEAR**

1. In column 4, line 16 (Page 7, Specification, (02/13/2004), line 9): "N+" should read as - - N<sup>+</sup> - -.
2. In column 11, line 4-5 (Page 9, Specification, (02/13/2004), line 21): "The Peptides," should read as - - the peptides, - -.
3. In column 12, line 9 (Page 21, Specification, (02/13/2004), line 20): "software)" should read as - - software) - -.
4. In column 59, line 59 (Page 86, Specification, (02/13/2004), line 12): "DEA" should read as - - DIEA - -.
5. In column 179, line 56 (Page 222, Specification, (02/13/2004), line 8): "monoisotopic)," should read as - - monoisotopic); - -.
6. In column 180, line 28 (Page 223, Specification, (02/13/2004), line 7): "1-{[cyclopropyl]" should read as - - 1-{1-[cyclopropyl] - -.
7. In column 196, line 39 (Page 241, Specification, (02/13/2004), line 8): ")4,7" should read as - - )-4,7 - -.
8. In column 199, line 19 (Page 244, Specification, (02/13/2004), line 17): "21b)" should read as - - 21h) - -.
9. In column 203, line 53 (Page 249, Specification, (02/13/2004), line 11): "21d)" should read as - - 21d) - -.
10. In column 208, line 29 (Page 3, Claims, (06/04/2009), Claim 1, line 7): in Claim 1 "CF<sub>3</sub>" should read as - - CF<sub>3</sub>, - -.
11. In column 210, line 9 (Page 6, Claims, (06/04/2009), Claim 2, line 6): in Claim 2 "(C=)" should read as - - (C=O) - -.
12. In column 210, line 16 (Page 6, Claims, (06/04/2009), Claim 2, line 10): in Claim 2 "CF<sub>3</sub>" should read as - - CF<sub>3</sub>, - -.
13. In column 210, line 25 (Page 6, Claims, (06/04/2009), Claim 2, line 16): in Claim 2 "C<sub>6</sub>alkyl)" should read as - - C<sub>6</sub>-alkyl) - -.
14. In column 210, line 65 (Page 7, Claims, (06/04/2009), Claim 3, line 16): in Claim 3 "CF<sub>3</sub>" should read as - - CF<sub>3</sub>, - -.
15. In column 211, line 2 (Page 7, Claims, (06/04/2009), Claim 3, line 19): in Claim 3 "(C<sub>1</sub>C<sub>6</sub>)" should read as - - (C<sub>1</sub>-C<sub>6</sub>) - -.

16. In column 211, line 4 (Page 7, Claims, (06/04/2009), Claim 3, line 20): in Claim 3 "(C<sub>1</sub>C<sub>6</sub>)" should read as - - (C<sub>1</sub>-C<sub>6</sub>) - -.
17. In column 212, line 15 (Page 9, Claims, (06/04/2009), Claim 4, line 2): in Claim 4 "(C<sub>1</sub>-C<sub>6</sub>)" should read as - - (C<sub>1</sub>-C<sub>6</sub>) - -.

Respectfully submitted,

Date 4/26/2011

/Serena Farquharson-Torres/  
Serena Farquharson-Torres, Reg. No. 54,093  
Attorney/Agent for Applicant

Sanofi-aventis U.S. Inc.  
U.S. Patent Operations  
Mail Code: BWD-303A  
1041 Route 202-206  
Bridgewater, New Jersey 08807  
Telephone (908) 231-2836  
Telefax (908) 231-2626  
Sanofi-aventis U.S. Docket No. DEAV2003/0072 US CNT

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,652,007

Page 1 of 2

APPLICATION NO.: 10/779,439

ISSUE DATE : January 26, 2010

INVENTOR(S) : Stefanie Flohr et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 4, line 16, delete "N+" and insert - - N<sup>+</sup> - -, therefor.

In column 11, line 4-5, delete "The Peptides," and insert - - the peptides, - -, therefor.

In column 12, line 9, delete "software)" and insert - - software) - -, therefor.

In column 59, line 59, delete "DEA" and insert - - DIEA - -, therefor.

In column 179, line 56, delete "monoisotopic)," and insert - - monoisotopic); - -, therefor.

In column 180, line 28, delete "1-{[cyclopropyl]" and insert - - 1-{1-[cyclopropyl] - -, therefor.

In column 196, line 39, delete ")4,7" and insert - - )4,7 - -, therefor.

In column 199, line 19, delete "21b)" and insert - - 21h) - -, therefor.

In column 203, line 53, delete "2 Id)" and insert - - 21d) - -, therefor..

In column 208, line 29, in claim 1, delete "CF<sub>3</sub>" and insert - - CF<sub>3</sub>, - -, therefor.

In column 210, line 9, in claim 2, delete "(C=)" and insert - - (C==O) - -, therefor.

In column 210, line 16, in claim 2, delete "CF<sub>3</sub>" and insert - - CF<sub>3</sub>, - -, therefor.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2*

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,652,007

Page 2 of 2

APPLICATION NO.: 10/779,439

ISSUE DATE : January 26, 2010

INVENTOR(S) : Stefanie Flohr et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 210, line 25, in claim 2, delete "C<sub>6</sub>alkyl)" and insert - - C<sub>6</sub>-alkyl) - -, therefor.

In column 210, line 65, in claim 3, delete "CF<sub>3</sub>" and insert - - CF<sub>3</sub>, - -, therefor.

In column 211, line 2, in claim 3, delete "(C<sub>1</sub>C<sub>6</sub>)" and insert - - (C<sub>1</sub>-C<sub>6</sub>) - -, therefor.

In column 211, line 4, in claim 3, delete "(C<sub>1</sub>C<sub>6</sub>)" and insert - - (C<sub>1</sub>-C<sub>6</sub>) - -, therefor.

In column 212, line 5, in claim 4, delete "(C<sub>1</sub>-C<sub>6</sub>)" and insert - - (C<sub>1</sub>-C<sub>6</sub>) - -, therefor.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2*

## Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.